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After decades of successful organ transplantation clinicians
continue to be troubled by the increasing incidence of
cancers under maintenance immunosuppression. In this
study, we examined rates of malignancies in 2419 renal
transplant recipients transplanted in our institution between
1978 and 2005. In renal transplant recipients the cumulative
incidence of cancer after 25 years was 49.3% for all tumors
and 39.7% excluding non-melanoma skin cancers, compared
with 21% for a normal sex- and age-matched population. The
most frequent tumors observed were non-melanoma skin
cancers (20.5%), kidney cancers (12.0%), and cancers of the
pharynx, larynx, or oral cavity (8.2%). The general increase of
cancer risk was 4.3-fold. Independent risk factors for the
development of a tumor were male gender, older recipient
age, the presence of preformed antibodies before
transplantation, and the time on immunosuppression.
Interestingly, the use of IL-2-receptor antagonists
significantly reduced the tumor risk of transplant recipients.
The tumor risk between immunosuppressive drugs typically
used for maintenance immunosuppression was not
significantly different. However, mammalian target of
rapamycin (mTOR) inhibitor-based immunosuppressive
protocols showed a clear tendency for lower malignancy
rates. De novo malignancies following renal transplantation
represent a serious problem endangering the prognosis of
otherwise successfully transplanted patients. Future studies
will have to address whether optimized immunosuppressive
regimens including mTOR-inhibitors are capable of reducing
the incidence or preventing the development of
posttransplant malignancies.
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With the improved long-term outcome of renal allograft
recipients, malignant tumors become a leading cause of late
death. As compared with an age- and sex-matched popula-
tion or with patients undergoing dialysis, organ-transplant
recipients have an increased incidence of cancer. With regard
to de novo malignancies, a conservative report indicates that
immunosuppressed organ allograft recipients have a three- to
four-fold increased risk of developing cancer in general and
up to 500-fold higher incidence of certain types of cancer.1
Further burdens are to be expected in an aging population of
transplant recipients with well-functioning allografts. In fact,
it is expected that cancer will surpass cardiovascular
complications as the leading cause of death in transplant
patients in the coming years.
The etiology of posttransplant malignancy is believed to
be multifactorial in nature and probably involves impaired
immunosurveillance of neoplastic cells as well as depressed
antiviral immune activity, with a number of common
posttransplant malignancies thought to be viral-related. In
addition, immunosuppressive agents may cause DNA
damage, interfere with normal DNA repair mechanisms,
and may promote tumor progression by upregulation of
various cytokines such as transforming growth factor-b1,
IL-10, or vascular endothelial growth factor.2 The incidence
of neoplasmas increases with time and the intensity of
immunosuppression3 and many of these arising tumors have
features that differ from those seen in the general population.
Also, neoplasmas that manifest during immunosuppressive
therapy are biologically more aggressive than those that occur
in the general population.1
It is difficult to ascertain precisely the incidence of most
tumors and to compare their rates of occurrence with those
in the general population. The main information on cancer
in the renal transplanted patient comes from the Cincinnati
Transplant Tumor Registry, established and subsequently
maintained by Penn since the 1970s,1 the Collaborative
Transplant Study,4 and the Australian and New Zealand
Transplant Registry.5 However, reporting of cancer to
registries is often incomplete and probably underestimates
the true cancer incidence. This observational cohort study
examined the risk and the distribution of malignancy in renal
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transplant recipients of greater Munich area. We also
attempted to identify specific risk factors associated with a
higher tumor risk for transplanted patients.
RESULTS
Cancer incidence after renal transplantation
In this study, a total of 2419 patients (including 421
retransplants and 189 living related donations) with a
complete follow-up were included. The mean time of
follow-up was 9.576.7 years, representing more than
22 500 patient–years of follow-up. There were no noticeable
aspects in the general study population with respect to
demographics and baseline characteristics apart from a
higher percentage of males than females. The demographics
of patients with and without a tumor are shown in Table 1.
Significant differences were found for male gender, age at
transplantation, and time on immunosuppression.
During the observation period, 498 cases of de novo
malignancy were recorded in 421 patients, resulting in an
overall tumor incidence of 21%. The mean time from
transplantation to malignancy diagnosis was 6.475.4 years
(median 5.0 years).
The cumulated tumor incidence data reveals a signifi-
cantly higher tumor incidence in transplanted patients than
an age- and sex-matched normal population of the greater
Munich area. After 25 years of immunosuppression, the
cumulative tumor incidence for all cancers was 49.3%,
excluding 39.7% for non-melanoma skin cancers. At the
same time the expected cumulative tumor incidence was
21.7% for a corresponding normal population (Figure 1a).
Interestingly, the increase of incidence of malignancies
after transplantation appears to occur immediately after
transplantation. Transplant recipients develop 45% of all
tumors within the first 5 years after transplantation and 71%
of all tumors within the first 10 years, whereas in the normal
population tumor incidence gradually increases with time
(Figure 1b).
Distribution of tumors and relative tumor risk in renal
transplant recipients
Quantitatively, the most frequent tumors in the transplant
situation were non-melanotic skin cancers (20.5%) followed
by renal cell carcinomas (12.0%) and cancers of the pharynx,
larynx, and the oral cavity (8.2%). Within the non-melanotic
skin cancers, basal cell carcinomas (11.5%) showed a slightly
higher frequency as squamous cell carcinomas (9.0%). The
absolute numbers per tumor entity are shown in Figure 2.
To compare the tumor development of transplant patients
with a normal population, we calculated the relative tumor
risk on the basis of an age- and sex-matched population of
the greater Munich area. Compared with a normal popula-
tion, transplanted patients had a 4.3 times higher risk of
developing any kind of cancer. However, this risk was not
evenly distributed across all tumor types. Tumors such as
lung, colorectal, breast, and prostate cancer showed only a
slightly increase in renal transplant recipients, whereas several
tumor entities could be clearly identified as transplant-
related. Among those were post-transplant lymphoprolifera-
tive disorders (PTLDs), cancers of the pharynx, larynx and
the oral cavity, renal cell cancers, non-melanoma skin
cancers, and Kaposi sarcomas. The relative tumor incidence
for the different tumor entities is shown in Table 2.
Effect of the initial immunosuppressive regime on de novo
tumor development
As almost all transplant recipients will require long-term,
effective immunosuppression, it is tempting to speculate
whether the class of immunosuppressive agent could
Table 1 | Demographics
Patients with tumor Patients without tumor All patients
Number of patients (n) 421 1998 2419
Retransplanted patients (n) 56 365 421
Living-related donations (n) 36 153 189
Gender (f/m) 134/287* 707/1291* 841/1578
Race (n) — —
Caucasian 2385 (98.6%)
Asian 29 (1.2%)
Indian/African 5 (0.2%)
Age at transplantation (years, mean7s.d.) 47.7712.4* 44.0713.4* 44.7713.3
Observation time (years, mean7s.d.) 11.876.6* 9.076.5* 9.576.7
Time on immunosuppression (years, mean7s.d.) 9.576.5* 6.975.8* 7.376.0
Age at tumor diagnosis (years, mean7s.d.) 55.4711.2 —
o30 n=11
30–60 n=296
460 n=191
Patients with CMV viremia after transplantation 62 (14.7%)** 315 (15.8%)** 377 (15.6%)
Tumors 498 0 498
CMV, cytomegalovirus.
*P=0.001 tumor vs without tumor.
**Not significant.
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potentially affect the development of cancers. Therefore, we
further analyzed the effect of our different immunosuppres-
sive protocols used over the time. The corresponding
Kaplan–Meier estimates were based on the maintenance
immunosuppression patients received at their discharge,
3 weeks after transplantation.
With the introduction of more powerful immunosup-
pressive regimes the tumor incidence over time increased:
azathioprine (AZA)ocyclosporine (CsA)oCsA/AZAotacro-
limus (TAC)oTAC/mycophenolate mofetil (MMF)oCsA/MMF.
mTOR-inhibitor (sirolimus (SRL))-based therapies showed a
clear trend toward a lower tumor risk than all other therapy
groups. Although, under this therapy no tumors were
observed, this difference was not significant owing to the
relatively low number of patients and the short observation
period. A MMF-based therapy was used in a significantly
older patient population (60.4710.1 versus 43.5712.8) than
the other protocols and therefore confounds the interpreta-
tion. However, in all protocols where MMF was used in
combination therapies with either CsA or TAC, the addition
of MMF increased the tumor development than the
corresponding calcineurin inhibitor (CNI)-based therapies
(Figure 3a).
In consideration of the recurrent nature of non-melanoma
skin cancers, we separately analyzed the effects of immuno-
suppressive agents on the total tumor episodes. Interestingly,
using this approach we found a significant impact of TAC
and TAC/MMF on the recurrence of basal cell carcinomas
(BCCs) and squamous cell carcinomas (SCCs). All other
immunosuppressive agents showed no difference, except the
above-mentioned potential protective effect of SRL on skin
cancer development (Figure 3b).
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Figure 1 | De novo malignancies after transplantation.
(a) Cumulative tumor incidence after renal transplantation. The
reference population represents a sex- and age-matched population
of the greater Munich area. (b) Tumor occurrence in relation to the
time after transplantation.
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Figure 2 | Absolute numbers of tumors detected in 2419 renal transplant recipients. Numbers on bars represent the absolute number.
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To identify finally the individual risk of each major
immunosuppressive agent we performed multivariate ana-
lyses using the Cox proportional hazard model. Although the
univariate analysis suggests clear differences between the
immunosuppressive regimes the multivariate analysis could
not identify a significant difference between the individual
immunosuppressive agents. Again, SRL and combinations of
SRL and CNIs showed a clear trend toward a lower tumor
incidence, but did not reach statistical significance because of
the short observation period and the relatively small patient
numbers. The Kaplan–Meier estimate as well as the multi-
variate analysis further revealed no significant effect of
polyclonal induction antibodies, such as antithymocyte
globulin or antilymphocyte globulin on overall tumor
development, but there appeared to be a slight protective
effect for the use of IL-2-receptor antagonists. (Figure 4a).
However, subanalyses among the different tumor entities
revealed a higher risk for PTLDs after induction therapy with
mono- and polyclonal antibodies, but not for the use of IL-2-
receptor antibodies. This effect of mono- and polyclonal
induction on PTLD development was already evident in the
first 5 years after transplantation (Figure 4b). The hazard
ratio for each immunosuppressant and induction antibody is
depicted in Table 3.
Independent risk factors for de novo malignancies after renal
transplantation
Significant independent risk factors for the development of a
de novo malignancy were male gender, older age (450 years
of age), the presence of preformed antibodies before
transplantation and the total time on immunosuppression.
Conversely, younger female patients were at a significant
lower risk for the development of a de novo malignancy.
Interestingly, a history of cancer had no influence on the
development of a secondary tumor (Table 4).
DISCUSSION
Early diagnosis and treatment of posttransplant malignancies
is an important emerging challenge in transplantation
medicine. An even greater challenge is the prevention and
management of malignancies. Documentation of tumors
arising de novo after transplantation as well as elucidation of
their association with particular immunosuppressive treat-
ment regimens is the first step in this direction.
Studies involving transplant registry data are, by their
nature, subject to certain limitations and constraints. For
example, there is no control over the completeness or detail
of the malignancy data recorded in these registries. Therefore,
one has to assume a high number of unreported tumor cases,
Table 2 | Tumor incidence and relative tumor risk as compared with an age-/sex-adjusted normal population
Cancer site Observed Expected RR 95% CI
All registerable malignancy 498 114.90 4.33 4.02–4.67
Skin
Skin (non-melanotic) 111 2.11 52.70 44.79–61.76
Melanoma 21 5.08 4.13 2.78–5.98
Gastrointestinal
Esoephagus, stomach, hepatobiliary 10 7.33 1.36 0.75–2.34
Colorectal 22 17.12 1.28 0.87–1.84
Genitourinary
Kidney 60 3.41 17.60 14.06–21.86
Tx-kidney 1 0 0
Bladder, urothel 17 6.05 2.81 1.80–4.24
Prostata CA 33 16.18 2.04 1.50–2.74
Ovary, testes 5 3.77 1.33 0.57–2.84
Cervix, vulva, vagina 21 4.75 4.42 2.98–6.40
Hematolymphatic
PTLD (vs NHL) 32 3.77 8.50 6.21–11.45
Leukemia 4 1.83 2.19 0.76–5.12
Mult. myeloma, plasmozytoma 8 1.09 7.33 3.69–13.40
Others
Pharynx, larynx 41 3.19 12.85 9.76–16.72
Thyroid 10 1.96 5.09 2.79–8.72
Breast 28 19.22 1.46 1.04–2.00
Lung 28 10.48 2.67 1.90–3.68
Liver 8 2.02 3.96 1.99–7.23
CNS 8 2.01 3.99 2.00–7.28
Kaposi sarkoma 8 0.06 142.32 71.59–259.94
Sarcoma others 4 1.18 3.38 1.17–7.90
CUP 11 2.36 4.67 2.64–7.79
Unclassified 7 0 0
CA, cancer; CNS, central nervous system; CUP, carcinoma of unknown primary; NHL, non-hodgkin lymphoma; PTLD, post-transplant lymphoproliferative disorder; RR, relative
risk.
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which subsequently leads to an underestimation of the real
problem. In contrast, results from single center studies are
often not significant owing to small patient numbers or a
short observation period. In this study, we tried to solve the
above-mentioned problems by reassessing 3275 renal trans-
plant recipients by direct interview or questionnaires given to
our collaborating nephrology/dialysis centers in charge of our
transplanted patients. To be most rigorous in this, all patients
with incomplete follow-up were excluded for further analysis.
By using this approach we ended up with a study population
of 2419 patients.
The data from our study confirm the clinical impression
of an alarming increase in cancer in transplanted patients
than sex- and age-matched normal population. After 25 years
of immunosuppression, almost half of the patients are at risk
to develop any kind of tumor. In our population, skin cancers
accounted for approximately 20% of these tumors. This is in
principal accordance with the latest ANZDATA registry data,
showing a cumulative tumor incidence of approximately 75%
within the same time interval.6 However, in Australia and
New Zealand the number of skin cancers is dramatically
higher, accounting for more than 40% of all tumors,
reflecting the importance of regional differences and co-
carcinogenes (e.g., sun exposure; Australia versus Central
Europe). Interestingly, the increase of incidence of malig-
nancies after transplantation appears to occur immediately
after transplantation Almost 50% of all de novo malignancies
become clinical evident within the first 5 years after
transplantation, reflecting the direct impact of immunosup-
pression (e.g., infections with oncogenic viruses or carcino-
genic effects) on tumor development in transplanted patients.
Another explanation for this phenomenon is that immuno-
suppression antedates tumor diseases, which would remain
dormant in individuals sufficiently protected by immuno-
logical and non-immunological surveillance mechanisms.
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Figure 3 | Immunosuppressive regimes and tumor development.
(a) Effect of the initial immunosuppression on total tumor
development. Significance (Po0.05) 1vs MMF; 2vs CsA, CsA/AZA, CsA/
MMF, TAC, TAC/MMF, MMF; 3vs AZA, CsA/AZA, CsA/MMF, TAC/MMF,
MMF; 4vs AZA, CsA, MMF, 5vs AZA, CsA, SRLþ -MMF/CsA; 6vs AZA,
MMF; 7vs AZA, CsA; 8vs AZA, CsA, CsA/AZA, SRLþ -MMF/CsA
(b) Effect of the initial immunosuppression on skin cancer episodes.
The initial immunosuppression was defined as the
immunosuppressive regime at discharge (B3 weeks after
transplantation). At this time all patients were still on steroids.
Significance (Po0.05) 1not significant; 2vs CsA, CsA/AZA, CsA/MMF,
TAC, TAC/MMF, MMF; 3vs AZA, CsA/MMF, TAC, TAC/MMF, MMF;
4vs AZA, 5vs AZA, CsA; 6vs AZA, CsA; 7vs AZA, CsA; 8vs AZA, CsA.
Kaplan–Meier estimates.
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Figure 4 | Induction therapy and tumor development. (a) Effect of
induction treatment on overall tumor development. No induction
was compared with IL2-R antagonists or depleting antibodies
(e.g., antithymocyte globulin, antilymphocyte globulin, OKT-3).
(b) Effect of induction treatment on PTLD development. Depleting
antibodies are compared with IL2-R antagonists or no induction.
Kaplan–Meier estimates.
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In absolute numbers, the most frequent tumors in our
population were non-melanoma skin cancers, kidney cancers,
and cancers of the pharynx, larynx, and the oral cavity.
Whereas skin cancers and cancers of the pharynx, larynx, or
oral cavity seem to be clearly transplant related, the high rate
of kidney cancers may be owing to selection bias of patients
with an underlying kidney disease, which itself bears a higher
risk for kidney cancer, such as acquired cystic kidney disease.
Calculating the relative tumor risk, we could identify a
number of cancer entities, which have a significantly higher
relative risk in transplanted patients than the general
population. Besides the above mentioned tumors, cancers
of the cervix, vulva or vagina, thyroid cancers, PTLDs, and
Kaposi sarcomas fall into this category. Many of these tumors
are also associated with the infection of oncogenic viruses,
which might in part explain the disproportional high
incidence in transplanted patients. Among the known
oncogenic viruses are human papilloma viruses,7,8 which
are associated with cervix carcinomas and carcinomas of the
skin, Epstein-Barr –viruses, which are frequently found in
PTLDs9,10 and human herpes virus 8,11 which is considered
as responsible for the development of Kaposi sarcomas. In
contrast, cancer rates for some of the most common tumors
in the general population, such as colon, lung, prostate, and
breast cancer, were only slightly increased.
To date, however, it is not clear what really drives the
tumorigenesis in the transplant setting. End-stage renal
failure per se seems to be associated with an excess risk of
cancer in dialysis patients, which is especially high in younger
patients and gradually diminishes with age.12 Therefore,
transplantation and subsequent immunosuppression add to
the increased cancer risk of dialysis patients. In contrast, one
might speculate that successful transplantation could also
reverse some of the unfavorable effects of dialysis, thus
putting these patients back to the risk of normal individuals.
It is reasonable to hypothesize that immunosuppression
weakens the immunological surveillance mechanisms and
therefore favor tumor development. However, there is also
experimental evidence and every-day experience that in an
immunocompetent host the immune system is not fully
capable of sequestering immunologically escaped tumors.13
To bring these two contradictory hypotheses together, one
has to assume that in case of virus-induced tumors, the
immune system might play a dominant role, whereas in
non-virus-induced tumors non-immunologic surveillance
mechanisms, such as DNA repair and the induction of
p53-dependent apoptosis of cancer cells might be more
important. AZA and CNIs have been shown to impair these
non-immunological surveillance mechanisms.2,14,15
Besides the inevitable need for immunosuppression in a
transplant situation, the kind of immunosuppressive agent
could potentially affect the development of cancers. The
Kaplan–Meier estimates of the different immunosuppressive
strategies suggest that by using more powerful immunosup-
pression, in particular calcineurin inhibitors, during the last
decades the cumulative tumor risk increased. As patients
demographics and comedications are not completely com-
parable within the different groups one has to interpret these
results with caution. Moreover, we calculated our data on the
basis of the initial immunosuppression at the time of
discharge. This may fail to capture the majority of a patient’s
immunosuppressive experience. Not surprisingly, the multi-
variate analysis relativizes much of the findings in the
univariate Kaplan–Meier estimates. Nevertheless, these data
are one of the first attempts for an approximation to this
problem. In our view the cautious conclusion of these data is
that especially CNIs may contribute to the increase in cancer
and TAC may enhance the recurrence of non-melanoma skin
Table 3 | Number of patients and number of observed cancers
in relation to the initial immunosuppression
IS Group All cancers Non-melanoma skin cancer
AZA 51/249 12/249
CsA 252/1052 87/1052
CsA/AZA 123/613 42/613
CsA/MMF 16/91 6/91
TAC 30/161 9/161
TAC/MMF 12/58 10/58
MMF 14/127 8/127
SRL/MMF 0/58 0/58
AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; SRL, sirolimus;
TAC, tacrolimus.
Table 4 | Major risk factors for malignancy after kidney
transplantation (Cox proportional hazards analysis)
RR (95% CI) P-value
Sex (male vs female) 1.30 (1.07–1.57) 0.008
Age at transplantation
o16 years 0.52 (0.21–1.28) 0.157
17–33 years 0.53 (0.40–0.71) o0.001
34–50 years (reference) 1.00 —
51–67 years 1.78 (1.46–2.17) o0.001
468 years 1.61 (0.86–2.99) 0.133
Pretransplant malignancy 1.00 (0.65–1.55) 0.987
PRAs
0% (reference) 1.00 —
1–100% 2.12 (1.33–3.37) 0.002
Time on immunosuppression 1.12 (1.02–1.23) 0.012
Immunosuppression at discharge
CsA 0.90 (0.61–1.33) 0.591
TAC 0.97 (0.58–1.62) 0.902
AZA 0.84 (0.67–1.04) 0.111
MMF 1.32 (0.87–2.01) 0.194
SRL 0.22 (0.03–1.58) 0.132
Antibody induction
None (reference) 1.00 —
IL-2-receptor antibody 0.57 (0.34–0.93) 0.026
OKT-3 0.78 (0.41–1.48) 0.454
Polyclonal antibody 0.84 (0.65–1.08) 0.183
AZA; azathioprine; CsA, cyclosporin; MMF, mycophenolate mofetil; PRA, preformed
antibody; SRL, sirolimus; TAC, tacrolimus.
1276 Kidney International (2007) 71, 1271–1278
o r i g i n a l a r t i c l e CD Wimmer et al.: De novo malignancy after renal transplantation
cancer. In contrast, the suggested particular protumoral effect
of AZA on skin cancers could not be shown in our patients.
These results, however, are in accordance with a recent study
by Herman et al.,16 who studied the effect of CsA and AZA
on DNA repair. They found that inhibition of DNA repair is
significantly lower in CsA-treated peripheral blood mono-
nuclear cells and in kidney transplanted patients than AZA.
In contrast to other authors we cannot confirm a protective
effect of MMF on tumor development.4 An exceptional
feature of mTOR inhibitors, however, seems to be the
antitumoral potency. Although we only could identify a clear
trend toward a lower incidence of cancers with the mTOR-
inhibitor SRL, a cohort study with sufficient statistical power
will be needed to validate this trend. Meanwhile, the
antitumoral effects of mTOR inhibitors are not only shown
in numerous preclinical studies,17 but also in a relevant
number of randomized clinical trials.18 Another very
interesting finding of this study is that induction therapy
does not necessarily increase tumor incidences in renal
transplant recipients. In contrast, our data show that the use
of IL-2-receptor antagonists may even have a protective effect
in terms of tumor development. These results correspond to
recent data published by Kasiske et al.19 The exact mechanism
why IL-2-receptor antagonists lead to a reduction of
tumors is not clear, but it is reasonable to assume that by
using a ‘malignancy-inert’ induction regime subsequent
immunosuppression can be kept down to a low index.
PTLDs, however, seem to have an exceptional position. In
this particular tumor entity mono- and polyclonal induction
regimes are associated with a significant higher tumor
risk than IL-2-receptor antagonist, induction or no induc-
tion.
Currently, the price for a successful ‘anti-rejection therapy’
may be paid in form of a high incidence of posttransplant
malignancies. Understanding of underlying pathogenetic
mechanisms responsible for the increased malignancy risk
in transplanted patients is only the start of the journey that
must be taken to reduce the rising impact of cancer on the
quality of life and the longevity of transplanted patients.
Tailored immunosuppressive therapy, targeted not only at the
individual’s risk of allograft rejection but also their risk of
cancer and determining appropriate renal population-screen-
ing strategies combined with early treatment programs, may
impact on mortality and morbidity.
MATERIALS AND METHODS
In this cohort observational study, 3275 eligible patients were
reviewed for the development of cancer after successful renal
transplantation (graft function 490 days). Data were obtained from
our local transplant registry, medical records, and spontaneous
reports of eligible patients transplanted at our institution between
1978 and 2005. In 2005, all collaborating dialysis centers and general
practitioners in charge of our transplanted patients underwent an
additional inquiry to capture not reported malignancies. Incomplete
medical information was clarified by telephone interviews with the
corresponding physicians. To be most rigorous in this analysis, 856
(26.1%) patients with no or incomplete follow-up for primary
(development of any malignancy within the observation period) and
secondary study end points were excluded from further analysis.
Recurrent preexistent malignancies and tumors becoming clinically
evident within 90 days after transplantation were disregarded.
Recurrent or multiple tumors of the same entity (e.g., non-
melanoma skin cancers) were counted as a single tumor event, when
not indicated otherwise. The initial immunosuppression was
defined as the posttransplant treatment at the time of discharge.
Owing to center policy this was 3 weeks after transplantation, later
changes of maintenance immunosuppression were disregarded. To
assess the relative tumor risk, our population was compared with a
standard, age- and sex-matched population from the greater
Munich area (data obtained from the Cancer Registry Munich,
http://trm.web.med.uni-muenchen.de). According to the Bavarian
Cancer Registry Law all clinics of the surgical sector, oncology
departments/physicians, pathological institutes, radiation therapy
clinics, health authorities, and civil registry offices (death certifi-
cates) are obliged to report all cases of malignancy to this registry.
Immunosuppression
There were three main periods of immunosuppressive regimes. The
first period of immunosuppression was from 1978 to 1982
AZAþprednisolon, from 1984 onwards low-dose cyclosporine
(target trough level: 150–200 ng/ml)þAZAþprednisolon. From
1996 onwards patients received an individualized immunosuppres-
sion with an induction therapy consisting of ATGFresenius and/or
basiliximab. Patients older than 50 years received a calcineurin-
inhibitor-free regime with MMF (2–3 g/day; target trough level:
2–4mg/ml)þ prednisolone, patients younger than 50, cyclosporine
low-dose (target trough level: 100–150 ng/ml)þMMF (2 g/day)-
prednisolone, and patients with preformed antibodies 420% TAC
(target trough level: 8–10 ng/ml)þMMF (2 g/day)þ prednisolone.
With the introduction of SRL some patients where treated with a
SRL-based (target trough level: 8–10 ng/ml) immunosuppression in
combination with cyclosporine, TAC, or MMF. Rejection episodes
were treated by a 3-day course of prednisolon with or without a 5-day
cycle of antithymocyte globulin, antilymphocyte globulin, or OKT-3.
Statistics
Results are expressed as the mean7s.d. when not indicated
otherwise. The w2 test was used for raw estimations of related
variables on tumor incidence after transplantation. The cumulative
tumor risk among transplanted patients was calculated for solid
tumors and skin cancer as well as PTLD. To demonstrate the
increased tumor risk in our transplanted patients, the estimated
tumor incidence of an age- and sex-matched standard population of
the greater Munich area as provided by the Tumor Registry Munich
was included in the plot (Figure 1a). For cumulative tumor
incidence probability estimations, the Kaplan–Meier method was
used. Comparisons between the groups were calculated using the
log-rank test. The Cox-regression analysis, using the ‘enter’
procedure, was applied to determine the influence of different
variables on relative risk for the development of different
malignancies. All calculations were performed with SPSS version
14.0 (SPSS Inc., Chicago, IL, USA).
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